No significant difference in the prognostic value of the 5th and 7th editions of <scp>AJCC</scp> staging for differentiated thyroid cancer

Vrachimis, Alexis; Gerß, Joachim; Stoyke, Maren; Wittekind, Christian; Maier, Tobias; Wenning, Christian; Rahbar, Kambiz; Schober, Otmar; Riemann, Burkhard

doi:10.1111/cen.12405

Cited by 13 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The recommended version is per definition the one that has last been published (in this case version 7 16 ). Although there has been some discussion in literature whether the changes that were made from version 5-6 were right, the present study, in contrast with Vrachimis et al 24 who found no difference, affirms the correctness of these changes as they resulted in a higher predictive power both with regard to DTC-related mortality and loss of life expectancy. A further problem with the TNM system is that when used in strict accordance with its definition, not all patients can be staged.…”

Section: Discussioncontrasting

confidence: 69%

See 1 more Smart Citation

The TNM system (version 7) is the most accurate staging system for the prediction of loss of life expectancy in differentiated thyroid cancer

Tanase

Thies

Mäder

et al. 2015

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 69%

“…13,14 Furthermore, the TNM system has gone through further iterations and is now in its 7th edition. 16 The newer versions of the TNM system (versions 6 and 7) come out as well 24 or better than the older ones (up to version 5). 25 Staging systems for DTC will only explain part of the total observed mortality.…”

Section: Introductionmentioning

confidence: 98%

The TNM system (version 7) is the most accurate staging system for the prediction of loss of life expectancy in differentiated thyroid cancer

Tanase

Thies

Mäder

et al. 2015

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…32 However, it was excluded from the parameters for DTC in the AJCC 8th edition, 3 and was considered useful for T3 staging in the AJCC 7th edition. 33 In this study, 25.7% of PTCs had minimal ETE and 2.6% had macroscopic ETE, however, was not an independent predictor of recurrence/ progression. There were several limitations to this study.…”

Section: Discussioncontrasting

confidence: 56%

Development of a risk scoring system for patients with papillary thyroid cancer

Pak

Kim

Suh

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

As the importance of personalized therapeutics in aggressive papillary thyroid cancer (PTC) increases, accurate risk stratification is required. To develop a novel prognostic scoring system for patients with PTC (n = 455), we used mRNA expression and clinical data from The Cancer Genome Atlas. We performed variable selection using Network‐Regularized high‐dimensional Cox‐regression with gene network from pathway databases. The risk score was calculated using a linear combination of regression coefficients and mRNA expressions. The risk score and clinical variables were assessed by several survival analyses. The risk score showed high discriminatory power for the prediction of event‐free survival as well as the presence of metastasis. In multivariate analysis, the risk score and presence of metastasis were significant risk factors among the clinical variables that were examined together. In the current study, we developed a risk scoring system that will help to identify suitable therapeutic options for PTC.

show abstract

“…The characteristics of the patients with PTC in this study are presented in Table I. The clinical stage was classified according to the American Joint Committee on Cancer (2010, 7th edition) tumor node metastasis (TNM) classification system (36). Patients were stratified into low- and high-risk PTCs according to the age, metastasis, extension and size risk-group classification (37).…”

Section: Methodsmentioning

confidence: 99%

Dynamic monitoring of circulating microRNAs as a predictive biomarker for the diagnosis and recurrence of papillary thyroid carcinoma

Zhang

Pan

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Circulating microRNAs (miRNAs/miRs) are considered to be potential biomarkers for numerous types of cancer. However, previous investigations into the expression of miRNAs in the serum of patients with papillary thyroid carcinoma (PTC) to predict diagnosis, prognosis and recurrence have reported conflicting results, and the role of miRNAs remains unclear. The present study dynamically assessed the circulating miRNA profile in patients with PTC and determined whether miRNAs in the serum could be used as biomarkers for the diagnosis, prognosis and recurrence of PTC. The expression levels of 3 reportedly upregulated miRNAs (miR-222, miR-221 and miR-146b) were analyzed using reverse transcription-quantitative polymerase chain reaction in 106 patients with PTC, 35 patients with benign thyroid nodules (BTN) and 40 paired controls. Patients with either newly diagnosed PTC or BTN who were undergoing thyroidectomies were recruited for a dynamic analysis of preoperative and postoperative serum miRNA levels. The results indicated that the expression levels of serum miR-222, miR-221 and miR-146b were significantly increased in patients with newly diagnosed PTC compared with controls and patients with BTN. Receiver operating characteristic curve analysis indicated that these miRNAs had a high diagnostic sensitivity and specificity for PTC prior to surgery. The expression of these three miRNAs in serum was significantly associated with poorer prognostic variables, including extrathyroidal invasion, metastatic lymph nodes and high-risk or advanced tumor node metastasis stage. More notably, the present study identified 2.36-, 2.69- and 5.39-fold reductions in the serum levels of miR-222, miR-221 and miR-146b, respectively, subsequent to patients undergoing a thyroidectomy. In addition, miR-222, miR-221 and miR-146b were overexpressed in the PTC with recurrence group compared with the PTC without recurrence group. Collectively, dynamic monitoring of circulating miRNAs may serve as a non-invasive biomarker for the diagnosis of PTC and the postoperative monitoring of its progression and recurrence.

show abstract

No significant difference in the prognostic value of the 5th and 7th editions of AJCC staging for differentiated thyroid cancer

Abstract: When comparing the stages of the seventh with the fifth edition of the AJCC for DTC, there was no significant difference in predicting DSS, EFS and OS.

Cited by 13 publications

References 21 publications

The TNM system (version 7) is the most accurate staging system for the prediction of loss of life expectancy in differentiated thyroid cancer

The TNM system (version 7) is the most accurate staging system for the prediction of loss of life expectancy in differentiated thyroid cancer

Development of a risk scoring system for patients with papillary thyroid cancer

Dynamic monitoring of circulating microRNAs as a predictive biomarker for the diagnosis and recurrence of papillary thyroid carcinoma

Contact Info

Product

Resources

About